Cyclerion Therapeutics (CYCN) said late Tuesday it relaunched as a neuropsychiatric company supported by a licensing agreement with the Massachusetts Institute of Technology for intellectual property.
The company said it will advance the development of therapies for neuropsychiatric conditions, starting with the phase 2 program for treatment-resistant depression.
The phase 2 proof-of-concept trial for its TRD program is expected to begin in 2026, with an initial data set expected the following year, the company said.
Cyclerion shares rose 43% during after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments